All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Most patients with chronic graft-versus-host disease (cGvHD) encounter skin involvement at some level (epidermal or sclerotic-type disease), with many also experiencing refractoriness to treatment.1 Hence, there is a need to develop an effective method for identifying patients who are at a greater risk of mortality. The use of patient-reported outcomes (PROs) as a clinical prognostic marker, for initial risk stratification and treatment selection of cutaneous cGvHD, has not yet been established.1
Here, we summarize an article by Baumrin et al.1 published in JAMA Dermatology on the association of PROs and mortality in patients with cGvHD who experience skin involvement.
Key learnings |
|
Subscribe to get the best content related to GvHD delivered to your inbox